Protocol Ledger

NCT03903822 · Phase II · COMPLETED

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT03903822 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-13 Enrollment: 292 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03903822
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)292 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03903822
Protocol FieldVerified Registry Value
NCT IdentifierNCT03903822
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment292 participants (ACTUAL)
Registered Start Date2019-05-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03903822
Hospital Research SiteLocationSite Profile
California Dermatology & Clinical Research InstituteEncinitas, CAOpen Hospital Dossier ->
First OC DermatologyFountain Valley, CAOpen Hospital Dossier ->
Clinical Science InstituteSanta Monica, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI